propiconazole has been researched along with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abad, S; Aumaitre, O; Belot, A; Blanchard-Delaunay, C; Cohen, P; Cohen-Aubard, F; Cottin, V; Crestani, B; Durel, CA; Durupt, S; Garzaro, M; Girszyn, N; Godeau, B; Guillevin, L; Hachulla, E; Hot, A; Jamilloux, Y; Jego, P; Killian, M; Lazaro, E; Le Gallou, T; Liozon, E; Martin, T; Moreuil, C; Papo, T; Perlat, A; Pillet, P; Pugnet, G; Samson, M; Terrier, B; Trefond, L | 1 |
1 other study(ies) available for propiconazole and Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
| Article | Year |
|---|---|
Orbital mass in ANCA-associated vasculitides: data on clinical, biological, radiological and histological presentation, therapeutic management, and outcome from 59 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Biopsy; Child; Drug Therapy, Combination; Eye Diseases; Female; France; Glucocorticoids; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Orbit; Orbital Diseases; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2019 |